Harvard’s Advice for NFL Player Health and Safety: The university’s independent study compared the NFL to five other North American sports leagues and made nine recommendations on how to help preserve the future of the game

MMQB, Sports Illustrated, May 15, 2017
Jenny Vrentas, quoting I. Glenn Cohen (Faculty Director) and citing Petrie-Flom's report

From MMQB:  Today’s 255-page report comes from Harvard Law School’s Petrie-Flom Center for health law policy, biotechnology and bioethics, and it compares the NFL’s policies and practices concerning player health against five other…

Read More

Harvard study suggests some NFL health and safety changes

Washington Post, May 15, 2017
Rick Maese, quoting I. Glenn Cohen (Faculty Director) and citing Petrie-Flom's report

From the Washington Post:  The physical demands are different. The types and severity of injuries are different. And the economics can vary wildly. But there are several common threads shared by professional sports leagues when it comes to health…

Read More

Harvard study: NFL should offer treatment for performance-enhancing drug users

Boston Globe, May 15, 2017
Travis Anderson, citing Petrie-Flom's report

From the Boston Globe:  The National Football League should consider providing treatment to any player caught using performance-enhancing drugs, according to a new Harvard University study. The recommendation was one…

Read More

Special Issue: Comparing Health Related Policies and Practices in Sports: The NFL and Other Professional Leagues

Journal of Sports Law and Entertainment, May 2017

The Journal of Sports and Entertainment Law at Harvard Law School published a Special Edition in May 2017, which prints in full the new report from the Petrie-Flom Center's Law & Ethics Initiative, part…

Read More

Sessions Suspends DOJ Forensic Science Commission (Audio)

Bloomberg Radio, April 11, 2017
David Sucherman, featuring Christopher Robertson (Academic Fellow Alumnus)

Christopher Robertson, professor of Law at the University of Arizona, and Brandon Garrett, professor at the University of Virginia School of Law, discuss U.S. attorney general Jeff Sessions’ announcement that he was terminating a Justice Department partnership with independent scientists to…

Read More

There’s a federal law to lower drug prices—and Louisiana may just use it

Ars Technica, May 4, 2017
Beth Mole, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Rachel Sachs, a law professor at Washington University in St Louis, told the KHN that this makes a good argument for summoning 28 U.S.C. § 1498. “The case is strong,” she said. If the law…

Read More

Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

Kaiser Health News, May 2, 2017
Sarah Jane Tribble, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Rachel Sachs, an associate professor of law at Washington University in St. Louis who attended the recent Johns Hopkins meeting, said she believes “the case is strong” in invoking Section 1498, even though pharmaceutical companies may…

Read More

Petrie-Flom Welcomes New Executive Director!

Petrie-Flom Center, May 10, 2017

We are thrilled to announce that Carmel Shachar, JD, MPH (HLS ’10, HSPH ’10), will join the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School…

Read More

Second Chance Kids

Frontline, PBS, May 2, 2017
Featuring Robert Kinscherff (Senior Fellow in Law and Applied Neuroscience)

On May 2, 2017, PBS's Frontline aired "Second Chance Kids," an exploration of the fight over the fate of juveniles in prison for murder, following a landmark Supreme Court ruling. Robert…

Read More

Should We Study Human Embryos Beyond 14 Days?

NOVA Next, April 26, 2017
Jenny Morber, quoting I. Glenn Cohen (Faculty Director)

From the article: [...] Some critics view calls to re-evaluate the 14-day rule as a pernicious moving of the goalposts. How meaningful can they be, the line of reasoning goes, if scientists want to change rules as soon as they bump up against them?

Read More

The new Oprah movie about Henrietta Lacks reopens a big scientific debate

Vox, April 24, 2017
Julia Belluz, quoting Holly Fernandez Lynch (Executive Director)

From the article: [...] Holly Fernandez Lynch, executive director of the Petrie-Flom Center for Health Law Policy,…

Read More

Prize fund for new antibiotics could mean true innovation

STAT News, April 25, 2017
Rachel E. Sachs (Academic Fellow Alumna)

A few weeks ago, a group of Democrats in both houses of Congress introduced the Improving Access to Affordable Prescription Drugs Act, a 129-page bill designed to lower drug prices while increasing innovation and cracking down on pharmaceutical company abuses (my thoughts on the bill are here). …

Read More

As a competitor encroached, Mylan took one state to court to push EpiPen sales, documents

STAT News, April 24, 2017
Ike Swetlitz, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article:  Three lawyers who reviewed the case at the request of STAT said they could not think of another instance when a pharmaceutical company sued to protect the status of its medication on a state…

Read More

Science Needs Your Cells: New York Times Op-Ed by Executive Director Holly Fernandez Lynch

New York Times, April 21, 2017
Holly Fernandez Lynch (Executive Director) and Steven Joffe

Biospecimens are essential to medical progress, but just medical waste to patients. Let's promote the science. From the op-ed: Many aspects of Ms. Lacks’s story reflect genuine injustice: the racism that characterized the…

Read More

PFC Spotlight: Student Fellow Alumnus Matthew Baum

Petrie-Flom Center, April 13, 2017

Matthew Baum was a Student Fellow for the 2013-2014 academic year, as a second year MD-PhD student in the Health Science and…

Read More

Death By 1,000 Cuts: How Republicans Can Still Alter Your Coverage

Kaiser Health News, April 10, 2017
Jay Hancock, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “It’s the single-biggest problem facing the exchanges,” said Rachel Sachs, a health law professor at Washington University in St. Louis. “That would make insurers not only exit tomorrow but also not want to offer plans in…

Read More

Congress and FDA nominee heap love on ‘adaptive trials’

Science, April 7, 2017
Kelly Servick, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “‘Adaptive clinical trials’ is one of those buzzwords that get brought up all the time,” says Rachel Sachs, an innovation and health law professor at Washington University in St. Louis in Missouri, and “there is definitely…

Read More

Scott Gottlieb: Conflicts surround Trump’s FDA pick

CNN, April 4, 2017
Sandee LaMotte, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Even some industry watchdogs are cautiously optimistic. In a New England Journal of Medicine perspective, Rachel Sachs, a Washington University associate professor of law who studies the FDA, points to Gottlieb's former ties to industry…

Read More

ICER Weekly View 03-31-17

ICER, March 31, 2017
Mitchell Stein, featuring blog post and NEJM article co-authored by Rachel E. Sachs (Academic Fellow Alumna)

From the review: Democrats’ New Drug Bill Improving Access to Affordable Prescription Drugs Act was introduced this week.  You can read the summary of the bill here.  Rachel Sachs takes a deep dive into the significance…

Read More

Anthem inches closer to full Obamacare exit

POLITICO, March 31, 2017
Dan Diamond, featuring blog post by Rachel E. Sachs (Academic Fellow Alumna)

From the newsletter: WHAT WE'RE READING Writing at Harvard’s “Bill of Health,” Rachel Sachs offers reasons to be bullish on Democrats’ drug price legislation but also picks apart its flaws. Read…

Read More